precipitated withdrawal following chronic opioid exposure in mice (Wu et al, 2015) . Thus, the nonopioid medication lorcaserin acts as a 5-HT 2C R agonist to influence aspects of opioid-evoked behaviors, suggesting that the 5-HT 2C R system may play a key role in the shared mechanisms for addiction and relapse vulnerability across psychostimulant and opioid drug classes.
The development of pain medications with analgesic efficacy, but reduced abuse liability, remains a high priority. Of equally high priority is the identification of therapeutic interventions that increase the maintenance of abstinence after cessation of opioid intake, even in high drug cue environments. A selective 5-HT 2C R agonist, such as lorcaserin, may provide a new avenue to add value to the outcomes of medication-assisted treatment in OUD (Figure 1 ). The next step is to expand the present data set to definitively test the hypotheses that lorcaserin inhibits opioid withdrawal and countermands stress-and/or opioid-triggered relapse events, for example. It is also possible that low doses of lorcaserin administered in combination with a partial μ-opioid agonist, with limited abuse liability but efficacy to suppress opioid-induced euphoria and withdrawal may reduce relapse risk via regulation of two signaling pathways. The neurochemical mechanisms and sites of action for 5-HT 2C R systems to control opioid-related behaviors are also of interest. Finally, preclinical studies to evaluate low-dose combinations of a partial μ-opioid agonist plus lorcaserin will provide insight into the potential for translational value in clinical trials geared to reduce the devastation of opioid overdose and OUD. Clinical studies have demonstrated a reproducible rapid antidepressant effect of low-dose ketamine in patients Figure 1 . Either a μ-opioid receptor partial agonist, a full 5-HT 2C receptor (5-HT 2C R) agonist, or a combination may afford gains in reducing relapse vulnerability and extending abstinence in opioid use disorder (OUD). Partial agonist actions at the μ-opioid receptor reduce the rewarding effects of opioids and withdrawal. The selective 5-HT 2C R full agonist lorcaserin suppresses oxycodone intake and associated cue reactivity as well as impulsivity. Low-dose combinations of a μ-opioid receptor partial agonist plus the non-opioid lorcaserin may provide an additional new avenue to support recovery in OUD patients. While the brain locus for a potential receptor-receptor interaction is unknown, both the μ-opioid receptor and 5-HT 2C R are co-expressed in nodes of the limbiccorticostriatal circuitry engaged in drug reward and relapse vulnerability. The FDA-approved OUD medication buprenorphine is a μ-opioid receptor partial agonist, but is not selective given its complex actions at δ-, κ-, and nociceptin/opioid receptor-like receptors (NOP or ORL-1) (Lutfy and Cowan, 2004) . Thus, other μ-opioid partial agonists may be needed to test the hypothesis that low-dose combinations with lorcaserin may add value in OUD medication-assisted therapy. (Autry et al, 2011; Nosyreva et al, 2013) . Consistent with the premise, ketamine's antidepressant effects have previously been shown to require AMPARs as NBQX, an AM-PAR antagonist, attenuates the antidepressant effects in rodents (Maeng et al, 2008; Autry et al, 2011) . Importantly, the model we proposed can account for the ineffectiveness of the NMDAR blocker memantine as an antidepressant in the clinic, as memantine-unlike ketamine-has a limited ability to block resting NMDAR function. However, a recent study challenged a key component of the model by suggesting that ketamine's antidepressant action is mediated by its metabolite 2R,6R-hydroxynorketamine (2R,6R-HNK), via the same signaling pathway and AMPARmediated synaptic potentiation as outline above (Autry et al, 2011) but in a NMDAR-independent manner (Zanos et al, 2016) . Validation of the same signaling pathway and effects on AMPAR-mediated potentiation-sans NMDAR block-prompted us to investigate the impact of 2R,6R-HNK on NMDAR-mediated neurotransmission. In recent experiments, we showed that 2R,6R-HNK can swiftly inhibit NMDAR transmission up to 50% at concentrations needed to trigger the intracellular signaling pathway involved in the potentiation of synaptic AMPAR responses, strongly supporting a role for NMDARblockade in this effect (Suzuki et al, 2017) .
FUNDING AND DISCLOSURE
Further characterization showed that the effect of 2R,6R-HNK on individual NMDA-mEPSCs mimicked those of ketamine, demonstrating that 2R,6R HNK -like ketamineselectively inhibits NMDARs while they are open (Suzuki et al, 2017) . Our study demonstrated that 50 μM 2R,6R-HNK blocks synaptic NMDARs and thus 2R,6R-HNK is not 'NMDAR-independent' in its action. Although we used a higher concentration than the 10 μM 2R,6R-HNK-suggested as the brain concentration in rodents following a behaviorally effective antidepressant dose of 10 mg/kg 2R,6R-HNK (Zanos et al, 2016 )-a recent study was not able to detect antidepressant effects of 10 mg/kg 2R,6R-HNK in the same behavioral paradigms (Yang et al, 2017) used by Zanos and colleagues, raising questions about the dose of 2R,6R-HNK necessary to mediate antidepressant effects and the brain concentration necessary to trigger the molecular pathway. Moreover, a mechanism, other than the demonstrated NMDAR-blockade of 2R,6R-HNK, remains to be demonstrated. The selective action of 2R,6R-HNK on open NMDARS indicate its efficacy as an antidepressant will strongly depend on factors that impact synaptic NMDAR channel opening. These factors may include glutamate release-probability, subunit composition of synaptic NMDARs, as well as levels of coagonists. Future studies will need to take into account these synaptic factors to elucidate the specific circuits involved in the antidepressant action of ketamine as well as 2R,6R-HNK. Overall, our findings demonstrate a critical role of NMDAR-block-mediated signaling in triggering the antidepressant effects of ketamine and 2R,6R-HNK.
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